arrow_back Back to App

NIH Reform: New Research Institutes for Allergy, Infectious, and Immunologic Diseases

This act splits the existing National Institute of Allergy and Infectious Diseases into three separate entities. The goal is to better focus research on allergies, infectious diseases, and immune system disorders. These changes could impact the efficiency of medical research, potentially leading to faster discoveries and improved treatments for diseases affecting many citizens.
Key points
Three new institutes are created: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases.
Directors of these new institutes will be appointed by the President with Senate approval for five-year terms, increasing public oversight.
The changes aim to streamline research and programs related to allergies, infectious diseases, and immune disorders, potentially leading to new therapies and better prevention.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_664
Sponsor: Sen. Paul, Rand [R-KY]
Process start date: 2025-02-20
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

NIH Reform Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_664.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-02-20.

What are the main provisions?

Key points include:

  • Three new institutes are created: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases.
  • Directors of these new institutes will be appointed by the President with Senate approval for five-year terms, increasing public oversight.
  • The changes aim to streamline research and programs related to allergies, infectious diseases, and immune disorders, potentially leading to new therapies and better prevention.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Paul, Rand [R-KY].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health